-+ 0.00%
-+ 0.00%
-+ 0.00%

Genentech says Phase II trial shows Roche’s enicepatide cuts HbA1c 2.65% at 48 weeks

PUBT·09/22/2026 05:05:26
Listen to the news
Genentech says Phase II trial shows Roche’s enicepatide cuts HbA1c 2.65% at 48 weeks
  • Genentech reported positive Phase II results for enicepatide, a once-weekly dual GLP-1/GIP agonist in adults with type 2 diabetes.
  • At 48 weeks, the 24 mg dose cut HbA1c by 2.65% from an 8.1% baseline.
  • Mean weight loss reached 15.5% at 48 weeks, with no plateau observed.
  • Discontinuations due to adverse events were 2% across enicepatide arms, versus 0% on placebo.
  • Genentech is running Phase III weight-management studies ENITH-1 and ENITH-2, targeting Phase III glycemic trials and CV outcomes studies in 1H 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roche Holding AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20260921428313) on September 22, 2026, and is solely responsible for the information contained therein.